TDOC
Teladoc Health, Inc. · Healthcare · Medical - Healthcare Information Services
Momentum inputs (comparable managers):
holder breadth +7.7% ·
share flow -12.3% ·
net new positions +7.1%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 117.98K | $661,394 | n/a | n/a |
| Q2 2026 | 112 | +6 | 112.98M | $926.42M | +10 | −4 |
| Q1 2026 | 109 | +2 | 103.34M | $549.43M | +5 | −3 |
| Q4 2025 | 106 | -1 | 112.74M | $760.88M | n/a | −1 |
| Q3 2025 | 19 | +1 | 71.06M | $549.33M | +2 | −2 |
| Q2 2025 | 16 | -1 | 66.90M | $582.70M | n/a | −1 |
| Q1 2025 | 14 | +1 | 30.12M | $239.71M | +1 | n/a |
| Q4 2024 | 13 | 0 | 34.32M | $311.99M | +2 | −2 |
| Q3 2024 | 12 | -1 | 22.43M | $205.74M | +1 | −2 |
| Q2 2024 | 13 | n/a | 27.83M | $272.20M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 6.55M | +15.4% | $52.11M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Point72 Asset Management ✦ | 6.51M | -41.8% | $51.82M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 5.01M | -1.3% | $39.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (passive) | 4.07M | +3.0% | $32.37M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 2.59M | -17.4% | $20.63M | 0.0% | ▼ Trim | 4 | SEC ↗ ×7 |
| 6 | Two Sigma Investments ✦ | 2.45M | +21.6% | $19.54M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 1.06M | +7.6% | $8.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 708.74K | +242.4% | $5.64M | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 9 | Millennium Management ✦ | 513.46K | -62.7% | $4.09M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 239.85K | -35.7% | $1.90M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 11 | Norges Bank ✦ (passive) | 178.00K | 0.0% | $1.42M | 0.0% | Held | 2 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 139.35K | +0.5% | $1.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Marshall Wace ✦ | 85.00K | New | $676,560 | 0.0% | New | 1 | SEC ↗ ×3 |
| 14 | Bridgewater Associates ✦ | 12.80K | -55.7% | $101,872 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $676,560 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 250.00K shares, $1,362 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 655 sh · $3,703
Officer, Director · 17.80K sh · $108,682
Officer · 7.36K sh · $46,356
Officer, Director · 18.33K sh · $115,478
Officer · 274 sh · $1,726
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology